Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Single-Arm, Phase II Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer.

NCT06678230 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06678230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Single-Arm, Phase II Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer.
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2024
Completion date
October 20, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer